Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

52.85 -0.72 (-1.34%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
LAWSUITS FILED AGAINST EAR, BMRN and RECAF -Jakubowitz Law Pursues Shareholders Claims
NEW YORK, NY / ACCESSWIRE / October 26, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies... 
From Jakubowitz Law
Via AccessWire
Topics Fraud Lawsuit
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
CLASS ACTION UPDATE for HYRE, WDH and BMRN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / October 26, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies.... 
From Levi & Korsinsky, LLP
Via AccessWire
Topics Initial Public Offering Lawsuit
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
BMRN ALERT: BioMarin Pharmaceutical Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of KPLT, BMRN and AMRN
NEW YORK, NY / ACCESSWIRE / October 26, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to... 
From The Klein Law Firm
Via AccessWire
Topics Fraud Intellectual Property
SHAREHOLDER ALERT: HEPS BMRN AMRN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, NY / ACCESSWIRE / October 26, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a... 
From The Law Offices of Vincent Wong
Via AccessWire
Topics Fraud Intellectual Property Lawsuit
Lawsuits Filed Against HYZN, NNOX and BMRN - Jakubowitz Law Pursues Shareholders Claims
NEW YORK, NY / ACCESSWIRE / October 25, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies... 
From Jakubowitz Law
Via AccessWire
Topics Fraud Lawsuit
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BMRN
From Rosen Law Firm
Via Business Wire
Barron's Latest Picks And Pans: Amazon, Apple, Chevron, Citigroup, Dell And More
This weekend's Barron's cover story features the latest results of the annual Barron's Big Money Poll. Other featured articles discuss which companies may benefit... 
Via Benzinga
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
NASDAQ:BMRN Investor Notice: Investigation over Possible Securities Laws Violations by BioMarin Pharmaceutical Inc.
San Diego, CA -- (SBWIRE) -- 09/22/2021 -- BioMarin Pharmaceutical Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Stifel Upgrades This Pharma Stock On Prospective FDA Approval For Dwarfism Drug
Stifel 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021
Upgrades According to Benchmark, the prior rating for TopBuild Corp (NYSE: 
Via Benzinga
Price To Earnings Ratio Insights For Biomarin Pharmaceutical
In the current market session, Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) is trading at $80.65, after a 5.06% drop. However, over the past month, the stock spiked by... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Pliant Therapeutics (NASDAQ:PLRX) shares rose 25.62% to $24.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $872.2... 
Via Benzinga
FDA Slaps Clinical Hold on BioMarin's Gene Therapy For Genetic Metabolism Disorder
​​​​​​BioMarin Pharmaceutical Inc (NASDAQ: BMRN) faces another setback in its gene therapy development program after the FDA placed the phenylketonuria (PKU) gene... 
Via Benzinga
Drug For Short-Limbed Dwarfism From Biomarin Wins European Approval
The European Commission (EC) has approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Voxzogo (vosoritide) once-daily injection to treat achondroplasia. The... 
Via Benzinga
Get Ready for a Potential Double in This Biopharmaceutical Stock in the Next 6 to 12 Months
All it will take is an FDA approval and a partial repeat of history. 
Via The Motley Fool
BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance
BioMarin Pharmaceutical Inc reported a 17% Y/Y increase in revenue to $501.7 million in Q2, beating the consensus of $448.8 million, attributable to Vimizim, Naglazyme, and Palynziq product revenues,... 
Via Talk Markets
BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) reported a 17% Y/Y increase in revenue to $501.7 million in Q2, beating the consensus of $448.8 million, attributable to... 
Via Benzinga
BioMarin Pharmaceutical inc (BMRN) Q2 2021 Earnings Call Transcript
BMRN earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Biomarin Pharmaceutical: Q2 Earnings Insights
Shares of Biomarin Pharmaceutical (NASDAQ:BMRN) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 143.75% over the... 
Via Benzinga
BioMarin Shares 5-Year Data From Open-Label Trial Of Hemophilia Gene Therapy
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has announced new data from open-label Phase 1/2 trial of valoctocogene roxaparvovec, an investigational gene therapy... 
Via Benzinga
BioMarin Expects EMA's CHMP Opinion In 1H 2022 For Its Hemophilia A Gene Therapy, FDA Resubmission In 2Q'22
The European Medicines Agency (EMA) has validated BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) marketing application seeking approval for hemophilia A gene... 
Via Benzinga
EMA's Advisory Committee Backs Approval Of BioMarin's Dwarfism Candidate
European Medical Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of BioMarin... 
Via Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
EMA Grants BioMarin's Request For Speedy Review of Hemophilia A Gene Therapy
The European Medicines Agency (EMA) has granted its request for accelerated assessment review to BioMarin Pharmaceutical Inc’s (NASDAQ: BMRN)... 
Via Benzinga
Five-Year Data Of BioMarin's Hemophilia Gene Therapy Shows Sustained Benefit
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has announced an update to its previously reported results from Phase 1/2 study of valoctocogene roxaparvovec, an... 
Via Benzinga
Biomarin Pharmaceutical Inc (BMRN) Q1 2021 Earnings Call Transcript
BMRN earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback